AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
New Chair brings extensive experience in global pharmaceutical and biotechnology leadership, healthcare innovation, and strategic drug development
Subscribe To Our Newsletter & Stay Updated